Transcatheter arterial embolization combined with hypoxia-replicative oncolytic adenovirus perfusion enhances the therapeutic effect of hepatic carcinoma

References

• HeimbachJKKulikLMFinnRSAASLD guidelines for the treatment of hepatocellular carcinomaHepatology201867135838028130846
   PubMed Web of Science ®Google Scholar
• SongPCaiYTangHLiCHuangJThe clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines from 2001 to 2017Biosci Trends201711438939828904327
   PubMed Web of Science ®Google Scholar
• ArizumiTUeshimaKMinamiTEffectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinomaLiver Cancer20154425326226734579
   PubMed Web of Science ®Google Scholar
• ErhardtAKolligsFDollingerMTACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multi-center, phase II SOCRATES trialCancer Chemother Pharmacol201474594795425173458
   PubMed Web of Science ®Google Scholar
• DufourJFHoppeHHeimMHContinuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I studyOncologist201015111198120421036880
   PubMed Web of Science ®Google Scholar
• LencioniRLlovetJMHanGSorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trialJ Hepatol20166451090109826809111
   PubMed Web of Science ®Google Scholar
• YangSLLiuLPJiangJXXiongZFHeQJWuCThe correlation of expression levels of HIF-1α and HIF-2α in hepatocellular carcinoma with capsular invasion, portal vein tumor thrombi and patients’ clinical outcomeJpn J Clin Oncol201444215916724374892
   PubMed Web of Science ®Google Scholar
• WarfelNAEl-DeiryWSHIF-1 signaling in drug resistance to chemotherapyCurr Med Chem201421263021302824735366
   PubMed Web of Science ®Google Scholar
• ShahTKrishnamacharyBWildesFHIF isoforms have divergent effects on invasion, metastasis, metabolism and formation of lipid dropletsOncotarget2015629281042811926305551
   PubMedGoogle Scholar
• DarbyIAHewitsonTDHypoxia in tissue repair and fibrosisCell Tissue Res2016365355356227423661
   PubMed Web of Science ®Google Scholar
• MujcicHHillRPKoritzinskyMWoutersBGHypoxia signaling and the metastatic phenotypeCurr Mol Med201414556557924894165
   PubMed Web of Science ®Google Scholar
• TennantDAFrezzaCMacKenzieEDReactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell deathOncogene200928454009402119718054
   PubMed Web of Science ®Google Scholar
• LuoDWangZWuJJiangCWuJThe role of hypoxia inducible factor-1 in hepatocellular carcinomaBiomed Res Int201420143–4111
   Google Scholar
• TangCMYuJHypoxia-inducible factor-1 as a therapeutic target in cancerJ Gastroenterol Hepatol201328340140523173651
   PubMed Web of Science ®Google Scholar
• AravalliRNCressmanENSteerCJCellular and molecular mechanisms of hepatocellular carcinoma: an updateArch Toxicol201387222724723007558
   PubMed Web of Science ®Google Scholar
• LiSYaoDWangLExpression characteristics of hypoxia-inducible factor-1α and its clinical values in diagnosis and prognosis of hepatocellular carcinomaHepat Mon2011111082182822224081
   PubMed Web of Science ®Google Scholar
• DaiCXGaoQQiuSJHypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgeryBMC Cancer2009941819948069
   PubMedGoogle Scholar
• YamamotoYNagasatoMYoshidaTAokiKRecent advances in genetic modification of adenovirus vectors for cancer treatmentCancer Sci2017108583183728266780
   PubMed Web of Science ®Google Scholar
• NiemannJKühnelFOncolytic viruses: adenovirusesVirus Genes201753570070628702840
   PubMed Web of Science ®Google Scholar
• WongthidaPDiazRMGalivoFVSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signalingMol Ther201119115015820959810
   PubMed Web of Science ®Google Scholar
• di PaoloNCBaldwinLKIronsEEPapayannopoulouTTomlinsonSShayakhmetovDMIL-1α and complement cooperate in triggering local neutrophilic inflammation in response to adenovirus and eliminating virus-containing cellsPLoS Pathog2014103e100403524651866
   PubMed Web of Science ®Google Scholar
• WangHWeiFLiHJiXLiSChenXCombination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse modelInt J Mol Med201331237738523229955
   PubMed Web of Science ®Google Scholar
• CuevasYHernández-AlcocebaRAragonesJSpecific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomasCancer Res200363206877688414583486
   PubMed Web of Science ®Google Scholar
• SteinwaerderDSLieberAInsulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivoGene Ther20007755656710819570
   PubMed Web of Science ®Google Scholar
• LeeJHChoiSHBaekMWCoCl2 induces apoptosis through the mitochondria- and death receptor-mediated pathway in the mouse embryonic stem cellsMol Cell Biochem20133791–213314023568501
   PubMed Web of Science ®Google Scholar
• WerthNBeerlageCRosenbergerCActivation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogensPLoS One201057e1157620644645
   PubMed Web of Science ®Google Scholar
• ZinkernagelASJohnsonRSNizetVHypoxia inducible factor (HIF) function in innate immunity and infectionJ Mol Med200785121339134618030436
   PubMed Web of Science ®Google Scholar
• PipiyaTSauthoffHHuangYQHypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expressionGene Ther2005121191191715690061
   PubMed Web of Science ®Google Scholar
• LozierJNCsakoGMondoroTHToxicity of a first-generation adenoviral vector in rhesus macaquesHum Gene Ther200213111312411779415
   PubMed Web of Science ®Google Scholar
• NalwogaHAhmedLArnesJBWabingaHAkslenLAStrong expression of hypoxia-inducible factor-1α (HIF-1α) is associated with Axl expression and features of aggressive tumors in african breast cancerPLoS One2016111e014682326760782
   PubMed Web of Science ®Google Scholar
• RankinEBFuhKCCastelliniLDirect regulation of GAS6/ AXL signaling by HIF promotes renal metastasis through SRC and METProc Natl Acad Sci USA201411137133731337825187556
   PubMed Web of Science ®Google Scholar
• CichońMASzentpeteryZCaleyMPThe receptor tyrosine kinase Axl regulates cell-cell adhesion and stemness in cutaneous squamous cell carcinomaOncogene201433324185419224056961
   PubMed Web of Science ®Google Scholar
• LencioniRde BaereTSoulenMCRillingWSGeschwindJFLipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety dataHepatology201664110611626765068
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• GongLWeiYYuXPengJLengX3-Bromopyruvic acid, a hexokinase II inhibitor, is an effective antitumor agent on the hepatoma cells: in vitro and in vivo findingsAnticancer Agents Med Chem201414577177624738957
   PubMed Web of Science ®Google Scholar
• PollutriDPatriziCMarinelliSThe epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinomaCell Death Dis201891429305580
   PubMedGoogle Scholar
• ShaoZLiYDaiWETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXRPharmacol Res201813518820030114438
   PubMed Web of Science ®Google Scholar
• KwonOJKimPHHuynSWuLKimMYunCOA hypoxia-and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomasClin Cancer Res201016246071608221169258
   PubMed Web of Science ®Google Scholar
• KietzmannTSamoylenkoARothUJungermannKHypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytesBlood2003101390791412393531
   PubMed Web of Science ®Google Scholar
• SumidaSMTruittDMLemckertAANeutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon proteinJ Immunol2005174117179718515905562
   PubMed Web of Science ®Google Scholar
• ParkBHLeeJHJeongJSVascular administration of adenoviral vector soaked in absorbable gelatin sponge particles (GSP) prolongs the transgene expression in hepatocytesCancer Gene Ther200512211612115578067
   PubMed Web of Science ®Google Scholar
• LiangBZhengCFengGExpression of hypoxia-inducible factor-1α in liver tumors after transcatheter arterial embolization in an animal modelJ Huazhong Univ Sci Med2009296776781
   Google Scholar
• LiangBZhengCSFengGSCorrelation of hypoxia-inducible factor 1alpha with angiogenesis in liver tumors after transcatheter arterial embolization in an animal modelCardiovasc Intervent Radiol201033480681219937023
   PubMed Web of Science ®Google Scholar
• YangGMengXSunLAntitumor effects of a dual cancer-specific oncolytic adenovirus on colorectal cancer in vitro and in vivoExp Ther Med20159232733425574193
   PubMed Web of Science ®Google Scholar
• PaccezJDVasquesGJCorreaRGThe receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic targetOncogene201332668969822410775
   PubMed Web of Science ®Google Scholar
• KanlikilicerPOzpolatBAslanBTherapeutic targeting of AXL receptor tyrosine kinase inhibits tumor growth and intraperitoneal metastasis in ovarian cancer modelsMol Ther Nucleic Acids2017925126229246304
   PubMedGoogle Scholar
• LeeHJJengYMChenYLChungLYuanRHGas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinomaCarcinogenesis201435476977524233839
   PubMed Web of Science ®Google Scholar
• LeeWPWenYVarnumBHungMCAkt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosisOncogene200221332933611821945
   PubMed Web of Science ®Google Scholar
• BruixJTakayamaTMazzaferroVAdjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialLancet Oncol201516131344135426361969
   PubMed Web of Science ®Google Scholar
• El-KhoueiryABSangroBYauTNivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialLancet2017389100882492250228434648
   PubMed Web of Science ®Google Scholar
• D’AloiaMMZizzariIGSacchettiBPierelliLAlimandiMCAR-T cells: the long and winding road to solid tumorsCell Death Dis20189328229449531
   PubMed Web of Science ®Google Scholar
• MelcherAParatoKRooneyCMBellJCThunder and lightning: immunotherapy and oncolytic viruses collideMol Ther20111961008101621505424
   PubMed Web of Science ®Google Scholar